SunTrust Robinson Humphrey raised its price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $28.00 (from $22.00) while maintaining a Buy ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst PT Change

Intra-Cellular Therapies (ITCI) PT Raised to $38 at BTIGMarch 2, 2018 3:13 AM Intra-Cellular Therapies (ITCI) PT Raised to $28 at CowenMarch 2, 2018 1:23 AM Intra-Cellular Therapies (ITCI) Misses Q4 EPS by 2cMarch 1, 2018 7:10 AM Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate UpdateMarch 1, 2018 7:00 AM